Sargent Investment Group LLC Sells 51,000 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Sargent Investment Group LLC decreased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 34.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,295 shares of the company's stock after selling 51,000 shares during the quarter. Sargent Investment Group LLC's holdings in Teva Pharmaceutical Industries were worth $1,511,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $29,000. Golden State Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $39,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $44,000. Compagnie Lombard Odier SCmA bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $54,000. Finally, Versant Capital Management Inc grew its holdings in Teva Pharmaceutical Industries by 437.8% during the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after buying an additional 4,312 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded down $0.23 during trading on Friday, reaching $16.08. 12,142,802 shares of the stock traded hands, compared to its average volume of 10,336,516. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The company has a 50-day moving average of $17.01 and a 200-day moving average of $16.91. The stock has a market capitalization of $18.44 billion, a P/E ratio of -13.98, a price-to-earnings-growth ratio of 0.94 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.48 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TEVA shares. Wall Street Zen cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday. UBS Group cut their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $24.71.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.